Save time and jump to the most important pieces.
Vivani Medical, Inc., formerly Second Sight Medical, Inc., (NASDAQ:VANI) (the "Company" or "Vivani") announced that trading of the Company's common stock on The Nasdaq Capital Market under the symbol "VANI" will commence today. Vivani is the combination of Nano Precision Medical, Inc. ("NPM") and Second Sight Medical Products, Inc. Closing of the merger was completed and announced yesterday, August 30, 2022. Vivani leverages proprietary technologies to develop and commercialize drug and device implants that treat patients with chronic diseases with high unmet medical need. Vivani has approximately $55 million in cash to advance the development of its portfolio, which includes lead asset N
Vivani will be traded under the new ticker (NASDAQ:VANI) Second Sight Medical Products, Inc.(NASDAQ:EYES) (the "Company" or "Second Sight"), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, announced today the completion of its merger with Nano Precision Medical, Inc. ("NPM"). NPM is a biopharmaceutical business which develops miniaturized, subdermal drug implants utilizing its proprietary NanoPortal™ technology to enable long-term, near constant-rate delivery of a broad range of medicines to treat chronic diseases. In connection with the merger, Second Sight changed its name to Vivani Medical, Inc
Second Sight to change its name to Vivani Medical, Inc. Second Sight Medical Products, Inc. (NASDAQ:EYES) (the "Company" or "Second Sight"), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced results of its annual meeting held on July 27, 2022, where the quorum was present. The formal results of the vote are included in a Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission. At the annual meeting, the shareholders voted on seven proposals: (1) approving the merger agreement with Nano Precision Medical, Inc. ("NPM") and the transactions contemplat
8-K - Vivani Medical, Inc. (0001266806) (Filer)
8-K - Vivani Medical, Inc. (0001266806) (Filer)
8-K - Vivani Medical, Inc. (0001266806) (Filer)
Second Sight to change its name to Vivani Medical, Inc. Second Sight Medical Products, Inc. (NASDAQ:EYES) (the "Company" or "Second Sight"), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced results of its annual meeting held on July 27, 2022, where the quorum was present. The formal results of the vote are included in a Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission. At the annual meeting, the shareholders voted on seven proposals: (1) approving the merger agreement with Nano Precision Medical, Inc. ("NPM") and the transactions contemplat
Second Sight Medical Products, Inc. (NASDAQ:EYES) (the "Company" or "Second Sight"), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced results of its annual meeting held May 28, 2021. Second Sight held its annual meeting online due to the COVID-19 pandemic. 60.98% of shareholders were present online or by proxy. Shareholders voted on four proposals: (1) electing six (6) members of the Board of Directors, to serve until the next annual meeting of shareholders in 2022 and until their successors are duly elected and qualified, (2) ratifying the appointment of Gumbiner Savett Inc. as our
Pixium Vision and Second Sight Medical Products announce business combination, creating a global leader in the sight restoration market Aims to create a global leader with potential to treat nearly all forms of blindnessCombined company to trade on Nasdaq and benefit from business and development synergies in the U.S. and EuropeTransaction provides broader access to financing sources to enable the combined company to accelerate the development and commercialization of its productsPixium Vision to remain listed on Euronext Growth and to be the largest shareholder of the new combined company listed on NasdaqTransaction expected to close in late Q1 or the beginning of Q2 2021Conference Call s
4 - Vivani Medical, Inc. (0001266806) (Issuer)
4 - Vivani Medical, Inc. (0001266806) (Issuer)
4 - Vivani Medical, Inc. (0001266806) (Issuer)
SC 13D/A - Vivani Medical, Inc. (0001266806) (Subject)
SC 13D - Vivani Medical, Inc. (0001266806) (Subject)
SC 13D/A - SECOND SIGHT MEDICAL PRODUCTS INC (0001266806) (Subject)
Nano Precision Medical's lead program (NPM-119) is a tiny subdermal implant of a GLP-1 receptor agonist to treat patients with Type 2 diabetes Second Sight will issue 134M shares to acquire full ownership of Nano Precision Medical. Second Sight shareholders will own ~23% of the combined company. Second Sight shareholders join NPM shareholders, including AstraZeneca which has been a strategic investor since 2016 Second Sight currently has over $69M to enable the advancement of NPM-119 through clinical proof of concept into a pivotal clinical trial and continued exploration of the visual prosthesis business opportunity Investor Conference Call Scheduled for Tuesday, February 8, 2022,
Gainers GigaCloud Technology Inc (NASDAQ:GCT) shares jumped 206% to close at $48.01 on Friday on continued volatility following the company's IPO on Thursday. Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) shares gained 80.2% to close at $0.91 after the company announced a marketing authorization application for pegzilarginase for the treatment of Arginase 1 deficiency has been submitted to and successfully validated by the European Medicines Agency. Social Capital Suvretta Holdings Corp. I (NASDAQ:DNAA) jumped 48.3% to settle at $14.07 following the completion of the SPAC merger with Akili. Axsome Therapeutics, Inc. (NASDAQ:AXSM) rose 40.4% to close at $59.55 after the company announce
Gainers GigaCloud Technology Inc (NASDAQ:GCT) shares jumped 145% to $38.45 on continued volatility following the company's IPO on Thursday. Volcon, Inc. (NASDAQ:VLCN) gained 51% to $2.7899 after the company announced it has received over $100 million of pre-production orders for the Stag Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) shares jumped 41.2% to $0.7131 after the company announced a marketing authorization application for pegzilarginase for the treatment of Arginase 1 deficiency has been submitted to and successfully validated by the European Medicines Agency. Axsome Therapeutics, Inc. (NASDAQ:AXSM) gained 41% to $59.84 after the company announced the U.S. FDA has approved Au
Gainers Helius Medical Technologies, Inc. (NASDAQ:HSDT) shares rose 159.3% to $1.67 in pre-market trading after dropping 13% on Tuesday. Eargo, Inc. (NASDAQ:EAR) shares rose 148% to $1.74 in pre-market trading. The company is scheduled to report Q2 earnings on Monday, August 8. Applied DNA Sciences, Inc. (NASDAQ:APDN) shares rose 63% to $4.57 in pre-market trading after jumping 297% on Tuesday. Applied DNA Sciences initiated analytical validation of a company-developed, PCR-based monkeypox virus test specific to the genetic signature of the monkeypox virus. Tuniu Corporation (NASDAQ:TOUR) shares rose 61% to $1.30 in pre-market trading after dropping over 9% on Tuesday. Chembio Diagnos